Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

Armodafinil vs modafinil?

See the DrugPatentWatch profile for Armodafinil

Armodafinil vs. Modafinil: A Quick Reference Guide

Feature Modafinil (Provigil®) Armodafinil (Nuvigil®)
Chemical composition Racemic mixture (R‑ and S‑enantiomers) Only the R‑enantiomer (active form)
Mechanism of action Dopamine reuptake inhibition + activation of orexin & histamine pathways Same as modafinil (R‑enantiomer drives most activity)
Approved uses Narcolepsy, shift‑work sleep disorder, obstructive sleep apnea (OSA) Same indications as modafinil
Typical dose (adult) 200 mg/day (single dose) 150 mg/day (single dose)
Half‑life 12–15 h 15–19 h (slightly longer)
Peak plasma concentration ~2–4 h after dosing ~2–5 h after dosing
Metabolism CYP3A4 & CYP2C19; forms active metabolites (e.g., modafinil N‑oxide) Primarily CYP3A4/3A5; fewer metabolites
Side‑effect profile Headache, nausea, dry mouth, insomnia, anxiety, dizziness Same as modafinil; similar or slightly lower incidence of nausea
Drug interactions Strong CYP3A4 inducer (e.g., carbamazepine); reduced by strong CYP3A4 inhibitors (e.g., ketoconazole) Same pattern; less susceptible to inhibition by CYP2C19 drugs
Special populations Pregnancy category B; use with caution in liver disease Same; slight caution in severe renal impairment
Cost & availability Generic options widely available; lower cost Less widely available; tends to be pricier

1. Chemical & Pharmacological Differences

  • Enantiomers
    • Modafinil contains both R‑ (active) and S‑ (less active) enantiomers.
    • Armodafinil contains only the R‑enantiomer, which is responsible for the bulk of wakefulness promotion.
  • Potency & Duration
    • Because it is “pure” R‑enantiomer, armodafinil has a slightly longer duration of action and may achieve comparable wakefulness at a lower dose.
    • Studies show similar efficacy for narcolepsy and shift‑work disorders, with modest benefits of armodafinil in maintaining alertness over a full 24‑h period.

2. Clinical Indications (Same for Both)

  • Narcolepsy – to reduce excessive daytime sleepiness.
  • Shift‑work Sleep Disorder – to improve alertness during night‑shift work.
  • Obstructive Sleep Apnea (OSA) – when sleep apnea is treated with CPAP, these drugs reduce residual daytime sleepiness.
  • Off‑label uses (reported but not FDA‑approved) – ADHD, depression, mild cognitive impairment, and even as “cognitive enhancers” in healthy adults.

Note: Always use under medical supervision; these agents can worsen certain psychiatric conditions (e.g., bipolar disorder, psychosis).

3. Dosing & Timing

Condition Modafinil Armodafinil
Narcolepsy 200 mg once daily (morning) 150 mg once daily (morning)
Shift‑work 200 mg 30–60 min before shift 150 mg 30–60 min before shift
OSA (adjunct) 200 mg daily 150 mg daily
  • Titration: Start at the lowest dose; increase by 50 mg (modafinil) or 25 mg (armodafinil) every 1–2 weeks if needed.
  • Meal Interaction: Food increases absorption for modafinil; for armodafinil the effect is less pronounced but still best taken on an empty stomach or with a light meal.

4. Pharmacokinetics & Metabolism

  • Modafinil
    • First‑order kinetics; saturation not reached at therapeutic doses.
    • Metabolized mainly by CYP3A4 (major pathway) and CYP2C19 (minor).
    • Excreted 70–80 % unchanged via kidneys; 20–30 % as metabolites.
  • Armodafinil
    • Similar overall profile; metabolism mainly CYP3A4/3A5 with fewer active metabolites.
    • Longer half‑life leads to less fluctuation in plasma concentration.

5. Safety & Side Effects

Symptom Modafinil Armodafinil
Headache 5–20 % 3–15 %
Nausea 1–10 % 1–7 %
Insomnia 1–8 % 1–6 %
Anxiety/irritability 2–9 % 1–6 %
Palpitations 1–3 % 1–2 %
Rare (1 % or less) Hypertension, rash, visual disturbances Similar

Long‑term safety remains under study. No evidence of dependency, but chronic use can mask underlying sleep disorders and lead to sleep debt.

6. Drug Interactions

  • Strong CYP3A4 inducers (e.g., carbamazepine, rifampin) → ↓ drug levels → reduced efficacy.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) → ↑ drug levels → increased side‑effects.
  • CYP2C19 inhibitors (e.g., fluconazole) → minimal effect on modafinil but slight effect on armodafinil.
  • Other stimulants (e.g., amphetamines, methylphenidate) → additive CNS stimulation; risk of tachycardia, hypertension.
  • Alcohol – may reduce alerting effect; avoid during treatment.

7. Practical Considerations for Patients

Factor Modafinil Armodafinil
Generic availability Widely available in many countries Limited generics; usually brand‑only in U.S.
Cost Lower due to generics Higher; sometimes reimbursed by insurers
Side‑effect profile Similar overall Slightly lower GI complaints
Duration of action ~12 h ~15 h (better for 24‑h shifts)
Dose adjustment in renal impairment Reduce dose by half if CrCl <30 mL/min Reduce dose similarly; caution if CrCl <15 mL/min
Pregnancy Category B; use only if benefits outweigh risks Same; avoid in pregnancy unless absolutely necessary

Bottom Line

  • Effectiveness: Both drugs are similarly effective for narcolepsy, shift‑work sleep disorder, and residual daytime sleepiness in OSA.
  • Duration: Armodafinil’s longer half‑life may give a smoother wakefulness profile, especially for night‑shift workers.
  • Side Effects: Comparable; armodafinil may cause slightly fewer GI complaints.


Other Questions About Armodafinil :

Buy armodafinil 150mg online? How much is armodafinil without insurance? Teva armodafinil? Cost of armodafinil? Armodafinil brand names? Armodafinil prix france? Armodafinil?

AI-Drug Label Prescribing Information Alignment Report

62
62%
Grade C

Partial

Mostly Aligned

Patient Risk: Low

Summary

Indication and dosing statements largely align with the label (narcolepsy, SWD, OSA; 150–250 mg daily dosing for OSA/narcolepsy; 150 mg for SWD; armodafinil 150 mg). Several PK, safety, and safety-management details are missing, mischaracterized, or not fully supported by the label (notably contraindications/boxed warnings, pediatric use, and certain renal/hepatic dosing nuances). Some statements conflict with the label (e.g., SWD dosing 200 mg before shift).

Category Scores

Indication
100
Excellent
Dosage
82
Good
Indication
100
Excellent
SpecificPopulations
70
Good
AdverseReactions
80
Good
Indication
100
Excellent

Accurate Statements

Modafinil is a racemic mixture (R- and S-enantiomers).
11
Armodafinil is the R-enantiomer (active form).
11
Armodafinil uses indications identical to modafinil (OSA, narcolepsy, SWD).
1
Typical dose (adult): Modafinil 200 mg/day (single dose).
2.1, 2.2
Armodafinil: 150 mg/day (single dose).
2.1, 2.2
Armodafinil Tmax ~2 hours (fasted); fed state may delay Tmax by ~2–4 hours.
12.3
Armodafinil: Peak plasma concentration ~2–5 hours after dosing.
12.3
Armodafinil: Metabolism involves CYP3A4/3A5 with metabolites; two major metabolites reach appreciable concentrations (acid and sulfone).
12.3
Armodafinil half-life is ~15 hours.
12.3
Headache, nausea, insomnia, anxiety/irritability, palpitations, and rare events occur with modafinil/armodafinil.
6
Strong CYP3A4 inducers/inhibitors affect modafinil/armodafinil levels; CYP2C19 interactions also noted; alcohol interaction; CNS stimulant interactions discussed.
7
Practical considerations: Modafinil widely available generically; armodafinil less so; cost considerations noted.
6
Armodafinil may have slightly fewer GI complaints than modafinil.
6
Armodafinil: The R-enantiomer drives wake-promoting activity and armodafinil has a longer half-life than modafinil.
12.3

Unsupported Statements

Modafinil mechanism of action includes activation of orexin and histamine pathways.
Label 12.1 indicates DAT inhibition and wake-promoting activity; no explicit statement about orexin/histamine pathway activation.
Modafinil excretion: 70–80% unchanged via kidneys; 20–30% as metabolites.
Label data indicate <10% excreted unchanged; majority excreted as metabolites.
Modafinil half-life: 12–15 h.
No explicit modafinil half-life value provided in the cited PK section for modafinil in the label excerpts.
Peak plasma concentration for modafinil ~2–4 h.
Peak time for modafinil is not specified in the provided label excerpts.
Dosing titration with stepwise increases (50 mg for modafinil; 25 mg for armodafinil) every 1–2 weeks.
Label does not specify titration guidelines in the provided sections.
Meal interaction: Modafinil absorption increases with food; armodafinil should be taken on an empty stomach or with a light meal.
Label indicates minimal food effect for armodafinil and potential delay in Tmax with food; no claim that modafinil absorption increases with food is supported by the provided label.
Bottom Line — Effectiveness: Both drugs are similarly effective for narcolepsy, SWD, and residual daytime sleepiness in OSA.
Label does not provide a single combined bottom-line conclusion; efficacy is demonstrated in separate lines of evidence per indication.
Bottom Line — Duration: Armodafinil’s longer half-life may provide a smoother wakefulness profile for night-shift workers.
Label provides pharmacokinetic half-life but does not frame a qualitative conclusion this way.
Bottom Line — Side Effects: Armodafinil may cause slightly fewer GI complaints.
Label data on GI complaints exist but a direct comparative statement is not explicitly stated as a bottom-line conclusion in the label.

Contradictions

Low

AI Statement
Dosing in SWD: Modafinil 200 mg 30–60 minutes before shift.

Label Reference
2.2

High

AI Statement
Modafinil excretion: 70–80% unchanged via kidneys; 20–30% as metabolites.

Label Reference
12.3

High

AI Statement
Peak plasma concentration: Modafinil ~2–4 h after dosing.

Label Reference
12.3

High

AI Statement
Pregnancy: Modafinil category B; use only if benefits outweigh risks.

Label Reference
8

Important Omissions

Contraindications (e.g., hypersensitivity to modafinil/armodafinil or excipients) and boxed-warning language (e.g., serious rash).
Importance: High
Pediatric safety and use in pediatric populations.
Importance: High
Boxed warnings (serious dermatologic reactions/DRESS/angioedema, etc.).
Importance: High
Detail on monitoring recommendations related to drug interactions and adverse events.
Importance: Moderate
Storage and handling specifics (where relevant).
Importance: Low

Safety Assessment

Potential Patient Risk: Low
Indication and dosing claims align with label; major safety gaps exist (contraindications, boxed warnings, pediatric use, precise renal dosing) that could affect safety if not correctly followed.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Missing/incorrect safety statements (contraindications, boxed warnings, pediatric use) and some dosing specifics (SWD dosing, renal dosing claims) not fully aligned with label.

Suggested Improvement
Cross-check against current FDA labeling for Provigil (modafinil) and Nuvigil (armodafinil): (a) explicitly state contraindications and boxed warnings if present; (b) provide accurate pregnancy/pediatric guidance per sections 8 and related; (c) verify renal/hepatic dose adjustments; (d) correct any dosing statements not supported by label (e.g., SWD modafinil 200 mg before shift); (e) distinguish PK statements that are supported vs. not in the provided label excerpts.